AbbVie shares climbed to an all-time high Tuesday, clearing a buy point. The company will announce earning Friday before the market opens.
News
Botox Maker Tops Buy Point, But Here Comes The Earnings Report
Licensing
02:40 PM ET 07/28/2026
AbbVie (ABBV) shares climbed to an all-time high Tuesday, clearing a buy point. But while the stock's action was bullish, a risk factor enters the picture with the company's earnings report just days away. The stock climbed more than 3% in above-average volume. It rose above an alternate entry at 261.63, which is also the previous high notched on July…
AbbVie, Inc. (ABBV) is currently at $231.34, up $14.86 or 6.86%
AbbVie, Inc. (ABBV) is currently at $226.39, up $9.90 or 4.57%
Abbott stock jumped early Thursday on better-than-expected second-quarter metrics. The company also raised its profit view.
Biotech firms are gaining major traction in 2026 due to the global pandemic. Take a look at some of the key features of biotech…
U.S. stocks up with Dow Jones gaining 200+ points. AbbVie Inc. announced acquisition of Apogee Therapeutics for $10.9B. Other…
The deal bolsters AbbVie's immunology and inflammation pipeline, answering a key investor question about what comes after Skyrizi.
